Description

• Title:
  Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
• Creator:
  Mazurek, Magdalena;
  Białowąs, Edyta;
  Dybała, Ewelina;
  Cuber, Iwona;
  Aghadi, Artur
• Description:
  Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive body weight is global and affects over 2 billion people around the world. Due to the increasing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with accompanying risk factors. To fight obesity, however, we primarily use lifestyle modification methods, such as a rational and balanced diet based on reduced caloric content and a low-carbohydrate diet. Another aspect is the use of the optimal amount of exercise of moderate intensity. Only the combination of all these methods gives a real chance for long-term weight loss and maintenance. Scientific research on GLP-1 analogue drugs such as semaglutide and liraglutide brings us a lot of prospects. The mechanism of their action is based on mimicking the natural GLP-1 secreted in the body. Aim of the study: The following article as an analysis of the current medical knowledge on the effectiveness and safety of obesity treatment with GLP-1 agonists based on available publications. Methods and materials: Literature review based on PubMed data using the following key words: obesity; semaglutide; Glucagon-like peptide-1 (GLP-1) agonists State of knowledge: GLP-1 receptor agonists are incretin drugs. This class of drugs has been approved by the FDA for the treatment of type 2 diabetes. Results: Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism.
• Object availability:
  free access
• Rights:
  Prawa autorskie (c) 2023 Magdalena Mazurek, Edyta Białowąs, Ewelina Dybała, Iwona Cuber, Artur Aghadi;
  https://creativecommons.org/licenses/by-nc-sa/4.0
• Date:
  2023.02.23
• Type:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Language:
  English
• Source:
  Journal of Education, Health and Sport; Vol. 13 No. 4 (2023); 196-205;
  Journal of Education, Health and Sport; Tom 13 Nr 4 (2023); 196-205;
  2391-8306
• Format:
  application/pdf
• Publisher:
  Nicolaus Copernicus University, Toruń, Poland
• Relation: https://apcz.umk.pl/JEHS/article/view/42726/34910
• Subject:
  obesity;
  agoniści glukagonopodobnego peptydu-1 (GLP-1);;
  semaglutyd
• Identifier: https://apcz.umk.pl/JEHS/article/view/42726
• Data provider:
  Akademicka Platforma Czasopism
• Can I use it?:
  seek permission
• Type:
  text